

URGOCELL START



SUPER-ABSORBENT LIPIDO-COLLOID NON-ADHESIVE DRESSING IMPREGNATED WITH NOSF


Indication: Exuding chronic wounds with risk factors of healing delay

- Inhibits excess proteases
- Promotes the action of growth factors
- Immediate and vertical absorption of exudate
- Re-balances the environment in chronic wounds

URGOCELL  START

Supplied in boxes of individually pouched and sterile dressings, ready to use

SIZES	UNITS PER BOX
10 x 12 cm	10 pouches
15 x 20 cm	5 pouches



DESCRIPTION

- Absorbent, sterile, non-occlusive lipido-colloid dressing impregnated with NOSF (issued from the Lipido-Colloid Technology, exclusive patented innovation by Urgo Laboratories).

COMPOSITION: **UrgoCell® Start** is a lipido-colloid dressing made of three layers:

- Non-adherent lipido-colloid contact layer (polyester mesh impregnated with hydrocolloid particles, vaseline particles and NOSF (Nano Oligo-Saccharide Factor)),
- Expanded super-absorbent polyurethane foam pad,
- Non-woven, semi-permeable 100% polyurethane backing.

METHOD OF STERILIZATION: Sterilized by ionizing radiation.

PROPERTIES

- In contact with wound exudate, the Lipido-Colloid Technology combined with NOSF (Nano Oligo-Saccharide Factor) provides optimal benefits for the wound healing process:
 - Thanks to the hydrocolloid particles, the Lipido-Colloid Technology forms a gel and creates a moist environment promoting the wound healing process. It allows effective movement of growth factors so that the key cells (fibroblasts, keratinocytes, macrophages) can exert their action in the wound healing process.
 - In contact with wound exudate, NOSF forms a gel which binds preferentially to damaged areas. It interacts with the wound environment by limiting the MMP's activity (Matrix MetalloProteases) which degrade the ECM (extracellular matrix) components. It also promotes the action of the growth factors.
- The super-absorbent pad is characterized by a high capacity for vertical absorption and retention of exudate.
- The semi-permeability of the external backing provides a high MVTR (moist vapour transmission rate), thus preventing from maceration.
- The use under compression therapy is possible due to the high ability to retain exudate.
- In contact with wound exudate, the hydrocolloid particles interact with the petroleum jelly component, to form a lipido-colloid gel creating a moist environment favourable for the healing process. The NOSF is maintained in this lipido-colloid gel, providing an activity on contact with the wound only.
- **UrgoCell® Start** does not adhere to the wound. Removal of the dressing is painless and atraumatic for the wound.

INDICATIONS

- **UrgoCell® Start** is indicated for the treatment of chronic exuding wounds after debridement, particularly if healing delay is clinically suspected.
- Non-adhesive, **UrgoCell® Start** is particularly recommended for wounds with damaged surrounding skin.

DIRECTIONS FOR USE

METHOD OF USE

- Cleanse the wound with saline solution.
- If an antiseptic is first used, rinse the wound thoroughly with saline solution before applying **UrgoCell® Start**.
- Remove the protective transparent films from the dressing.
- Apply **UrgoCell® Start** directly onto the wound.
- Secure **UrgoCell® Start** with a retention bandage (Nylex®).
- For the treatment of leg ulcers, a compression system bandage should be applied.
- **UrgoCell® Start** should be changed every 3 to 4 days depending on the condition of the wound.
- The minimum period of treatment with **UrgoCell® Start** is 4 to 5 weeks.

PRECAUTIONS

- In case of clinical signs of infection, prior treatment of infection is recommended before using **UrgoCell® Start**.
- Possible stinging or pain sensations have been reported, especially at the start of the treatment. These are related with the action on the healing process and rarely warrant discontinuation of the treatment.
- **UrgoCell® Start** should be stored flat, away from light, heat and moisture.
- Do not use if sterile protection has been damaged.

LEGAL STATUS